Discover and read the best of Twitter Threads about #Murcidencel

Most recents (4)

This draft guidance is wonderful in that FDA reminds us that there has been a long-standing precedent (decades) for use of external controls as "substantial evidence of effectiveness" and approval.

But is it relevant?...

fda.gov/media/164960/d…

$NWBO #Murcidencel Glioblastoma Image
This draft guidance is focused on "patient-level data" which might not relate to #Murcidencel - In that case, FDA would be able to cite the decades old precedent.

Recall that Avastin and Optune were both FDA approved but didn't improve survival in rGBM, unmet need.

$NWBO Image
In summary, this draft guidance is overall positive for $NWBO as it
1 shows FDA flexibility and precedent for use of external controls as substantial evidence of effectiveness
2 aims to formalize a portion of the precedent into official "guidance" for industry
$XBI Cancer Vaccine
Read 4 tweets
Combo data, combo patent.
$NWBO #Murcidencel
$MRK $BMY etc
CIs didn’t work, so synergy is *non-obvious*

Further, IF ANYTHING, field was maybe suggesting that neoadjuvant was only place it might work. BUT *unexpectedly* adjuvant works best.

Patentability = war, highly competitive, highly lucrative CI market

$NWBO $MRK #PD1 #Checkpoint
The combo data reduced this non-obvious, unexpected phenomenon to practice, in my opinion.

1 + 0 = 6

$NWBO $MRK
Read 4 tweets
Exploring Adjuvants with #DCVaxL: POLY ICLC TLR 3 Agonist adjuvant discussion, #DrLindaLiau, early trial P 1. Using adjuvants w/ #DCVaxL $NWBO #Murcidencel #DCVax

Survival Data w/Adjuvants, small early trial:
Fuller Discussion re early trial with #DCVaxL + adjuvants, including Poly ICLC:
Re single agent checkpoint inhibitors, without DCVaxL, in Glioblastoma:
Read 13 tweets
$NWBO #DCVaxL New name #murcidencel
SNO Abstract, just released, for presentation by #DrLindaLiau on November 20th:

Background: Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years.
We evaluated in a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival. Patients and

Methods: Newly diagnosed glioblastoma patients were randomized 2:1 to either murcidencel or placebo.
Under a crossover design, all patients could receive murcidencel following tumor recurrence. All parties remained blinded regarding treatments before recurrence. Patients thus received murcidencel at new diagnosis (nGBM) or at recurrence (rGBM) following crossover from placebo.
Read 17 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!